Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 8Recurrence 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Hodgkin Disease 1

Interventions

Rituximab 14Bortezomib 9Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5Filgrastim 5temsirolimus 4tanespimycin 4alvocidib 4Magnetic Resonance Spectroscopy 4Indium 4Cyclophosphamide 4ibritumomab tiuxetan 3Vorinostat 3Sirolimus 3Carboplatin 3sargramostim 2oblimersen 2ibrutinib 2belinostat 2Radiotherapy 2Pharmacogenomic Testing 2Methotrexate 2MK 2206 2Lenalidomide 2Interleukin-12 Subunit p35 2Interferon-alpha 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cyclosporine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Waldenstrom Macroglobulinemia × Chlorambucil × Clear all
NCT00608374 2013-08-26

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Completed
400 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡